Novikova · Nature communications 2021 · Multi-omic genomic integration and in vitro validation study · n=?

Integration of Alzheimer's disease genetics and myeloid genomics identifies disease risk regulatory elements and genes.

Cited 237 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Mechanistic computational genomics and in vitro cell model validation (Level 5 by design analogy)

PubMed 33712570 · doi:10.1038/s41467-021-21823-y · record verified 2026-08-29

What was done

Researchers integrated Alzheimer's disease (AD) genome-wide association study (GWAS) data with myeloid epigenomic and transcriptomic datasets from monocytes, macrophages, and microglia. Using analytical fine-mapping and integration methods, they linked myeloid enhancer activity to target gene expression and AD risk modification, and experimentally tested a candidate variant at the MS4A locus in human induced pluripotent stem cell (hiPSC)-derived microglia and brain tissue.

What was found

AD risk alleles were enriched specifically in active enhancers of monocytes, macrophages, and microglia. The authors mapped AD risk enhancers and nominated candidate causal target genes across 20 loci (including AP4E1, AP4M1, APBB3, BIN1, MS4A4A, MS4A6A, PILRA, RABEP1, SPI1, TP53INP1, and ZYX). A single candidate functional variant in the MS4A locus was identified and validated. The abstract reports no numerical metrics, effect sizes, or p-values.

Why it matters

The study maps non-coding Alzheimer's risk variants to specific myeloid enhancers and target genes, providing mechanistic candidates for how immune cell gene regulation influences disease susceptibility.

Limits

Sample sizes, donor counts, and quantitative metrics are omitted from the abstract. Most candidate regulatory elements and target genes remain computational nominations without experimental validation beyond the single MS4A locus. In vitro stem-cell-derived microglia may not fully capture in vivo human brain pathogenesis.

Cited by